Prevalence of metabolic syndrome in long-term survivors of hematopoietic stem cell transplantation

Abstract

Our purpose was to determine the prevalence and features of metabolic syndrome (MS) in a series of long-term hematopoietic stem cell transplantation (HSCT) survivors. We assessed the clinical, metabolic and endocrinological data, and plasma TNF, leptin, resistin and adiponectin levels relating to 85 HSCT recipients. MS was diagnosed on the basis of the National Cholesterol Education Program-Adult Treatment Panel III criteria. Its prevalence was compared with that observed in an Italian population, and its relationship with the clinical and laboratory parameters was assessed univariately and multivariately. Twenty-nine HSCT recipients had MS instead of the 12.8 expected (P<0.0001), with hypertriglyceridemia being the most common feature. Univariate analysis indicated that high insulin and leptin levels, low-adiponectin levels and hypogonadism were significantly related to a diagnosis of MS; multivariate analysis indicated plasma leptin, insulin resistance, age and hypogonadism. We conclude that HSCT recipients are at increased risk of a form of MS that has particular clinical features. Plasma leptin levels are independently related to MS, thus suggesting that leptin resistance may play a role as a pathogenetic clue, as in other conditions in which MS occurs as a secondary phenomenon. MS deserves consideration as a life-threatening complication in patients who are probably cured of their underlying disease.

Metabolic syndrome in adults who received hematopoietic stem cell transplantation for acute childhood leukemia: an LEA study

“…A higher risk for transplanted patients was confirmed by several other studies. [9][10][11][12][13] Some authors have shown an increase in MS prevalence in patients who underwent TBI; 9 our previous study was consistent with this hypothesis. However, the mechanism that underlies the pathophysiology of MS after HSCT is still poorly understood; most studies in this field have heterogeneous or small cohorts, making it difficult to draw definitive conclusions about prevalence or risk factors of MS in transplanted patients.…”

“…However, the mechanism that underlies the pathophysiology of MS after HSCT is still poorly understood; most studies in this field have heterogeneous or small cohorts, making it difficult to draw definitive conclusions about prevalence or risk factors of MS in transplanted patients. 9,10,[12][13][14] In this study, we aimed to describe the prevalence and cumulative incidence over time of MS and its components in a relatively large prospective cohort of adults surviving childhood AL who received an HSCT and to define risk factors for this condition.…”

Prevalence of the Metabolic Syndrome and Associated Factors in Korean Cancer Survivors

“…In long-term survivors of childhood cancer, the trends for increased risk of metabolic syndrome were observed in several studies (Talvensaari et al, 1996;Follin et al, 2006;Gurney et al, 2006;Oeffinger et al, 2006;Annaloro et al, 2008). As for survivors of adult-onset solid tumors, most studies were limited to some specific cancer types such as testicular cancer and prostate cancer (Nuver et al, 2005;Braga-Basaria et al, 2006;Haugnes et al, 2007).…”

Dyslipidemia and Metabolic Syndrome in Children and Teenagers After the Allogeneic Hematopoietic Stem Cell Transplantation

“…Частота метаболического синдрома и дислипиде-мии после алло-ТГСК у детей и взрослых достаточно высока и составляет 34-56 % [7]. По данным M. Taskinen et al [8], гипертриглицеридемия у детей после алло-ТГСК выявлена у 39 % пациентов, что существенно выше по сравнению с больными (8 %), получившими О р и г и н а л ь н ы е и с с л е д о в а н и я / О б з о р ы л и т е р а т у р ы только химиотерапию при лечении острого лимфо-бластного лейкоза (ОЛЛ).…”

“…Метаболический синдром был диагностирован только у 3 (4 %) пациентов, что ниже, чем в других ра-ботах [7], и может быть объяснено меньшим возрастом реципиентов, наблюдавшихся в нашем исследовании.…”